Investor’s Business Daily
Kymera Therapeutics Stock Scores Rising Relative Price Strength
On Monday, Kymera Therapeutics stock hit a key performance benchmark, with its Relative Strength (RS) Rating moving into the 90-plus percentile with an upgrade to 94, an increase from 88 the day before. When you’re researching the best stocks to buy and watch, keep a close on eye on relative price strength. Is Kymera Therapeutics Stock A Buy?